Abstract
This study examined the relationship between lifestyles (diet, sleep, and physical activity) and glucose responses at a personal level. 36 healthy adults in the Bay Area were monitored for their lifestyles and glucose levels using wearables and continuous glucose monitoring (NCT03919877). Gold-standard metabolic tests were conducted to phenotype metabolic characteristics. Through the lifestyle data (2,307 meals, 1,809 nights, and 2,447 days) and 231,206 CGM readings from metabolically-phenotyped individuals with normoglycemia or prediabetes, we found: 1) eating timing was associated with hyperglycemia, muscle insulin resistance (IR), and incretin dysfunction, whereas nutrient intakes were not; 2) timing of increased activity in muscle IS and IR participants was associated with differential benefits of glucose control; 3) Integrated ML models using lifestyle factors predicted distinct metabolic characteristics (muscle, adipose IR or incretin dysfunction). Our data indicate the differential impact of lifestyles on glucose regulation among individuals with different metabolic phenotypes, highlighting the value of personalized lifestyle modifications.
Competing Interest Statement
A.A.M. is currently an employee of Google, and A.D. is an employee of Calico Life Sciences. D.P. and T.M. are members of the scientific advisory board of January AI. M.P.S. is a co-founder and a member of the scientific advisory board of Personalis, Qbio, January AI, SensOmics, Protos, Mirvie, RTHM and Iollo. He is on the scientific advisory board of Danaher, Neuvivo and Jupiter. All other authors declare no financial or non-financial competing interests.
Clinical Trial
NCT03919877
Funding Statement
This study was funded by the National Institutes of Health (NIH)/NIDDK1R01 DK110186-01 (M.P.S. and T.M.) and the Stanford PHIND award (M.P.S.). This study is part of the Precision Diets for Diabetes Prevention clinical trial (NCT03919877). H.P. was supported by the NIH institutional research training grant NIH 2T32HL09804911 and the Stanford Lifestyle Medicine grant. Y.W. was supported by the American Diabetes Association grant 11-23-PDF-76. We also acknowledge the support of the Stanford Diabetes Research Center (P30DK116074).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board at Stanford University School of Medicine Human Research Protection Office gave ethical approval for this work (Institutional Review Board #43883).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request. All nonPHI data will be shared indefinitely on a publicly available database at the time of publication. The data include CGM (time-shifted), clinical information, and demographics. The study protocol is shared as a Supplementary Information.
